201 related articles for article (PubMed ID: 24907722)
1. Long-acting erythropoietin stimulating agents for persistent anemia after kidney transplant: risk factors and outcome.
Al-Otaibi T; Gheith O; Halim MA; Abu Attia H; Mansour H; Said T; Nair P; Balaha M; Nampoory MR
Exp Clin Transplant; 2014 Jun; 12(3):220-6. PubMed ID: 24907722
[TBL] [Abstract][Full Text] [Related]
2. A prospective protocol-based trial of darbepoetin alfa therapy to correct the early anemia following renal transplantation.
Pankewycz O; Kulaylat M; Fagan L; Matthews B; Kohli R; Laftavi MR
Transplant Proc; 2010 Nov; 42(9):3537-41. PubMed ID: 21094811
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of a simple dosage scheme to convert from shorter-acting erythropoiesis-stimulating agent to continuous erythropoietin receptor activator in kidney transplantation patients.
Sánchez-Escuredo A; Batista F; Cases A; Torregrosa JV
Transplant Proc; 2015; 47(1):73-5. PubMed ID: 25645774
[TBL] [Abstract][Full Text] [Related]
4. Proteinuria is a predictor of posttransplant anemia.
Bonofiglio R; Lofaro D; Greco R; Senatore M; Papalia T
Transplant Proc; 2011 May; 43(4):1063-6. PubMed ID: 21620053
[TBL] [Abstract][Full Text] [Related]
5. Treatment of anemia with erythropoietin-stimulating agents in kidney transplant recipients and chronic kidney disease-another drawback of immunosuppression?
Malyszko J; Glowinska I; Mysliwiec M
Transplant Proc; 2012 Dec; 44(10):3013-6. PubMed ID: 23195016
[TBL] [Abstract][Full Text] [Related]
6. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
[TBL] [Abstract][Full Text] [Related]
7. A monocentric observational study of darbepoetin alfa in anemic hepatitis-C-virus transplant patients treated with ribavirin.
Kamar N; Guitard J; Ribes D; Esposito L; Rostaing L
Exp Clin Transplant; 2008 Dec; 6(4):271-5. PubMed ID: 19338488
[TBL] [Abstract][Full Text] [Related]
8. [Long-acting erythropoetin efficacy in the treatment of nephrogenic anemia in patients with chronic kidney disease during predialysis stage].
Milovanov IuS; Milovanova LIu
Ter Arkh; 2012; 84(6):48-52. PubMed ID: 22997919
[TBL] [Abstract][Full Text] [Related]
9. Anemia control in renal transplant recipients receiving continuous erythropoietin receptor activator (C.E.R.A.) treatment: the AnemiaTrans Study.
Sánchez-Fructuoso AI; Ruiz JC; Torregrosa JV; González E; Gómez E; Gallego RJ; Troya MI; Jimenez C; Llamas F; Romero R; Bernis C; Crespo JF; Guirado L;
Adv Ther; 2012 Nov; 29(11):979-91. PubMed ID: 23160946
[TBL] [Abstract][Full Text] [Related]
10. Treatment of anemia with epoetin in kidney transplant recipients.
Bren A; Arnol M; Kandus A; Varl J; Oblak M; Lindič J; Pajek J; Knap B; Kovač D; Mlinšek G; Buturović-Ponikvar J
Ther Apher Dial; 2011 Jun; 15(3):257-60. PubMed ID: 21624072
[TBL] [Abstract][Full Text] [Related]
11. Treating Posttransplant Anemia With Erythropoietin Improves Quality of Life but Does Not Affect Progression of Chronic Kidney Disease.
Pile T; Raftery M; Thuraisingham R; Kirwan CJ; Harwood S; Yaqoob MM
Exp Clin Transplant; 2020 Feb; 18(1):27-33. PubMed ID: 31180297
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
13. Anemia in kidney transplants without erythropoietic agents: levels of erythropoietin and iron parameters.
Florit EA; Hadad F; Rodriguez Cubillo B; De la Flor JC; Valga F; Perez Flores I; Calvo Romero N; Valero San Cecilio R; Barrientos Guzman A; Sanchez Fructuoso A
Transplant Proc; 2012 Nov; 44(9):2590-2. PubMed ID: 23146464
[TBL] [Abstract][Full Text] [Related]
14. Darbepoetin-alfa in renal-transplant patients: an observational monocentric study.
Ribes D; Kamar N; Guitard J; Esposito L; Rostaing L
Clin Nephrol; 2008 Feb; 69(2):102-6. PubMed ID: 18218303
[TBL] [Abstract][Full Text] [Related]
15. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
Pfeffer MA; Burdmann EA; Chen CY; Cooper ME; de Zeeuw D; Eckardt KU; Feyzi JM; Ivanovich P; Kewalramani R; Levey AS; Lewis EF; McGill JB; McMurray JJ; Parfrey P; Parving HH; Remuzzi G; Singh AK; Solomon SD; Toto R;
N Engl J Med; 2009 Nov; 361(21):2019-32. PubMed ID: 19880844
[TBL] [Abstract][Full Text] [Related]
16. [Results of anemia treatment with darbepoetin alfa and erythropoietin beta in patients with chronic kidney disease].
Wanic-Kossowska M
Pol Merkur Lekarski; 2010 Jan; 28(163):13-7. PubMed ID: 20369716
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and determinants of anemia in the immediate postkidney transplant period.
Poesen R; Bammens B; Claes K; Kuypers D; Vanrenterghem Y; Monbaliu D; Evenepoel P
Transpl Int; 2011 Dec; 24(12):1208-15. PubMed ID: 21929730
[TBL] [Abstract][Full Text] [Related]
18. Reengineering clinical operations in a medical practice to optimize the management of anemia of chronic kidney disease.
Joy MS; Candiani C; Vaillancourt BA; Chin H; Hogan SL; Falk RJ
Pharmacotherapy; 2007 May; 27(5):734-44. PubMed ID: 17461709
[TBL] [Abstract][Full Text] [Related]
19. Hemoglobin maintenance and dosing strategies using intravenous continuous erythropoietin receptor activator in Japanese hemodialysis patients.
Hirai T; Nishizawa Y; Nakazono H; Asai M; Yamashita H; Sasaki A; Yamashita T; Yamashita K; Shigemoto K; Harada S; Mizuiri S
Ther Apher Dial; 2013 Oct; 17(5):498-503. PubMed ID: 24107278
[TBL] [Abstract][Full Text] [Related]
20. The impact of darbepoetin alfa in early post-transplant anaemia management: retrospective exploratory study.
Jiménez C; González E; Marqués M; Galeano C; Andrés A; Calvo N; Pascual J
Nefrologia; 2013 Jan; 33(1):107-15. PubMed ID: 23364633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
